Dr. Arpaporn Sutipatanasomboon is experienced in cell biology and molecular genetics research and is a registered patent agent with the Thailand Department of Intellectual Property. Her passion is to integrate early health technology assessment and intellectual property management to support decision makers, innovators and promote access to innovat

Dr. Teerawat Wiwatpanit is a biomedical scientist by training. His expertise includes early health technology assessment, innovation development, and biomedical engineering for disease modeling and drug testing. He is passionate about promoting an efficient innovation landscape and translating scientific discoveries into practical healthcare soluti

Asst. Prof. Dr. Wang Yi is a co-founder of Medical Innovation Development and Assessment Support (MIDAS). His research areas include early health technology assessment, traditional health technology assessment, population’s preference for health and healthcare, and economic evaluation/analysis using real-world data and observational data. He is als

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht for the CKD treatment and other related expenses.

Kidney failure (KF)[1] is a life-threatening disease that requires either kidney transplantation or dialysis for survival (1, 2). As of 2019, it was estimated that globally, 1.4 million deaths occurred on account of chronic kidney disease (CKD) (3). The cost of treatment for KF is also high, leading to catastrophic household expenditure to househo

66261068HM025L0Early Health Technology Assessment,pulmonary tuberculosis

In January 2019, the Minister of Health from Chhattisgarh state, India, reached out to International Health Policy Program (IHPP), a semi-autonomous research program in Thailand, to learn about the Thai experience of implementing Universal Health Coverage (UHC). The minister requested to meet with s

About this book First-of-its-kind resource exploring how cancer care fits into a general health system, contributed to by internationally eminent interdisciplinary experts Cancer Systems and Control for Health Professionals delivers a comprehensive overview of the subject of cancer control

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

Rapeepong Suphanchaimat1,2 Angkana Sommanustweechai1 , Chiraporn Khitdee1 , Chompoonut Thaichinda1 , Kanang Kantamaturapoj3 , Pattara Leelahavarong4 , Pensom Jumriangrit1 , Thitikorn Topothai1 , Thunthita Wisaijohn1 Weerasak Putthasri1 1International Health Policy Program (IHPP), Ministry of Publi